An Investigation of the Antidepressant Effects of the Glycine Receptor Antagonist AV 101 (4-chlorokynurenine) in Major Depressive Disorder
Phase of Trial: Phase II
Latest Information Update: 25 May 2018
At a glance
- Drugs AV 101 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 29 Jun 2017 According to a VistaGen Therapeutics media release, the company expects top-line results from the study during the first half of 2018.
- 13 Feb 2017 According to a VistaGen Therapeutics media release, U.S. National Institute of Mental Health (NIMH) is conducting this trial under VistaGens Cooperative Research and Development Agreement (CRADA) with the NIMH. Company anticipates that the NIMH will complete this study by the end of 2017.
- 20 Jan 2017 Planned End Date changed from 1 Dec 2019 to 31 Dec 2019.